enGene (NASDAQ:ENGN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.03), Zacks reports.
enGene Price Performance
Shares of NASDAQ ENGN traded up $0.08 during mid-day trading on Friday, reaching $3.33. The company had a trading volume of 48,040 shares, compared to its average volume of 129,156. enGene has a 1-year low of $2.65 and a 1-year high of $11.00. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $169.76 million, a PE ratio of -5.74 and a beta of -0.40. The company has a 50-day moving average price of $3.79 and a two-hundred day moving average price of $5.45.
Wall Street Analyst Weigh In
Several research firms recently commented on ENGN. Morgan Stanley lowered their target price on enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Piper Sandler began coverage on enGene in a research report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 target price on the stock. JMP Securities restated a "market outperform" rating and issued a $18.00 target price on shares of enGene in a research report on Tuesday, April 29th. Finally, HC Wainwright restated a "buy" rating and issued a $25.00 target price on shares of enGene in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $23.29.
Check Out Our Latest Stock Analysis on ENGN
enGene Company Profile
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
